Published in Nucl Med Biol on April 07, 2010
Prospective of ⁶⁸Ga-radiopharmaceutical development. Theranostics (2013) 1.32
A practical guide to the construction of radiometallated bioconjugates for positron emission tomography. Dalton Trans (2011) 1.28
Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer. Pharmaceuticals (Basel) (2014) 1.22
A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer. EJNMMI Res (2012) 1.15
Imaging key biomarkers of tumor angiogenesis. Theranostics (2012) 1.03
Site-Specific Labeling of scVEGF with Fluorine-18 for Positron Emission Tomography Imaging. Theranostics (2012) 0.86
Alternative Non-Antibody Protein Scaffolds for Molecular Imaging of Cancer. Curr Opin Chem Eng (2013) 0.83
New radiotracers for imaging of vascular targets in angiogenesis-related diseases. Adv Drug Deliv Rev (2014) 0.83
Positron emission tomography imaging of vascular endothelial growth factor receptor expression with (61)Cu-labeled lysine-tagged VEGF121. Mol Pharm (2012) 0.81
In vivo characterization of 68Ga-NOTA-VEGF 121 for the imaging of VEGF receptor expression in U87MG tumor xenograft models. Eur J Nucl Med Mol Imaging (2012) 0.79
In vivo evaluation of medical device-associated inflammation using a macrophage-specific positron emission tomography (PET) imaging probe. Bioorg Med Chem Lett (2013) 0.77
Imaging VEGF receptor expression to identify accelerated atherosclerosis. EJNMMI Res (2014) 0.75
(68)Ga-DOTA and analogs: Current status and future perspectives. Rep Pract Oncol Radiother (2014) 0.75
Hydroxypyridinone Chelators: From Iron Scavenging to Radiopharmaceuticals for PET Imaging with Gallium-68. Int J Mol Sci (2017) 0.75
Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging (2013) 3.61
The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging (2014) 3.40
Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med (2012) 3.31
Remission of major depression under deep brain stimulation of the lateral habenula in a therapy-refractory patient. Biol Psychiatry (2010) 2.71
Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine. Int J Radiat Oncol Biol Phys (2006) 2.48
68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem (2012) 2.31
Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis. Int J Cardiol (2011) 2.10
Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res (2007) 2.01
Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat Med (2007) 1.99
Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol (2008) 1.70
A history of the therapeutic use of liquorice in Europe. J Ethnopharmacol (2005) 1.65
Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses. Arch Dermatol (2007) 1.58
Shortened acquisition protocols for the quantitative assessment of the 2-tissue-compartment model using dynamic PET/CT 18F-FDG studies. J Nucl Med (2011) 1.57
131I-labeled peptides as caspase substrates for apoptosis imaging. J Nucl Med (2005) 1.54
Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET. Leuk Lymphoma (2007) 1.53
Radiopharmaceutical therapy of patients with metastasized melanoma with the melanin-binding benzamide 131I-BA52. J Nucl Med (2013) 1.53
Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res (2010) 1.52
Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts. Hepatology (2013) 1.52
(68)Ga-labeled peptides in tumor imaging. J Nucl Med (2005) 1.45
Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging (2014) 1.43
Amyoplasia associated with a balanced de novo insertion of a segment of the long arm of chromosome 5 into chromosome 2. Am J Med Genet (2002) 1.42
Darwinian molecular imaging. Eur J Nucl Med Mol Imaging (2009) 1.40
AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur Heart J (2012) 1.35
scVEGF microbubble ultrasound contrast agents: a novel probe for ultrasound molecular imaging of tumor angiogenesis. Invest Radiol (2010) 1.35
PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging (2013) 1.33
Analysis of in situ and ex vivo vascular endothelial growth factor receptor expression during experimental aortic aneurysm progression. Arterioscler Thromb Vasc Biol (2009) 1.30
18F-FDG kinetics and gene expression in giant cell tumors. J Nucl Med (2004) 1.29
Antiviral effects of Glycyrrhiza species. Phytother Res (2008) 1.29
Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies. Neurology (2014) 1.26
Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol (2003) 1.25
Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med (2005) 1.25
PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells. Blood (2010) 1.23
Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol Cancer Ther (2005) 1.16
Assessment of quantitative FDG PET data in primary colorectal tumours: which parameters are important with respect to tumour detection? Eur J Nucl Med Mol Imaging (2007) 1.15
Persistent umbilical discharge from an omphalomesenteric duct cyst containing gastric mucosa. Case Rep Pediatr (2012) 1.15
A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer. EJNMMI Res (2012) 1.15
Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol (2007) 1.14
Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys (2006) 1.11
T-helper cell 2-driven immunity in pregnancy as a determinant of antiplasmodial antibody half-life through regulation of Fc-receptor-mediated clearance. J Infect Dis (2013) 1.10
The pharmacokinetics of cell-penetrating peptides. Mol Pharm (2010) 1.10
Radioiodine therapy of hepatoma using targeted transfer of the human sodium/iodide symporter gene. J Nucl Med (2006) 1.09
Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging (2006) 1.09
Multiplexing with multispectral imaging: from mice to microscopy. ILAR J (2008) 1.08
Insulin-dependent diabetes mellitus is associated with infections through reduction of antibody response to T-cell-dependent antigens. Pediatr Infect Dis J (2013) 1.08
[¹⁷⁷Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging (2015) 1.08
Detection of cranial meningiomas: comparison of ⁶⁸Ga-DOTATOC PET/CT and contrast-enhanced MRI. Eur J Nucl Med Mol Imaging (2012) 1.07
Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study. J Nucl Med (2010) 1.06
Fusion of positron emission tomography (PET) and gene array data: a new approach for the correlative analysis of molecular biological and clinical data. IEEE Trans Med Imaging (2007) 1.06
GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog. J Nucl Med (2005) 1.06
Chaperone-targeting cytotoxin and endoplasmic reticulum stress-inducing drug synergize to kill cancer cells. Neoplasia (2009) 1.06
Reversal of vascular leak with imatinib: a role for IL-2? Am J Respir Crit Care Med (2014) 1.06
68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG. J Nucl Med (2007) 1.06
Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging (2006) 1.05
Surface immobilization of active vascular endothelial growth factor via a cysteine-containing tag. Biomaterials (2006) 1.04
DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging (2007) 1.03
Silica- and alkoxysilane-coated ultrasmall superparamagnetic iron oxide particles: a promising tool to label cells for magnetic resonance imaging. Langmuir (2007) 1.03
Imaging key biomarkers of tumor angiogenesis. Theranostics (2012) 1.03
Synthesis of p-(di-tert-butyl[(18)F]fluorosilyl)benzaldehyde ([(18)F]SiFA-A) with high specific activity by isotopic exchange: a convenient labeling synthon for the (18)F-labeling of N-amino-oxy derivatized peptides. Bioconjug Chem (2007) 1.03
In vivo tumor angiogenesis imaging with site-specific labeled (99m)Tc-HYNIC-VEGF. Eur J Nucl Med Mol Imaging (2006) 1.02
Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine. Oncotarget (2014) 1.02
Impact of angiogenesis-related gene expression on the tracer kinetics of 18F-FDG in colorectal tumors. J Nucl Med (2008) 1.01
A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy. Clin Cancer Res (2005) 1.01
RGD-labeled USPIO inhibits adhesion and endocytotic activity of alpha v beta3-integrin-expressing glioma cells and only accumulates in the vascular tumor compartment. Radiology (2009) 1.01
Gene therapy imaging in patients for oncological applications. Eur J Nucl Med Mol Imaging (2005) 1.01
Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease. Psychiatry Res (2007) 1.00
Prediction of short-term survival in patients with advanced nonsmall cell lung cancer following chemotherapy based on 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography: a feasibility study. Mol Imaging Biol (2007) 0.99
Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. Eur J Nucl Med Mol Imaging (2014) 0.98
Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab: the NEAR trial. Cancer (2011) 0.98
VEGF receptors and neuropilins are expressed in the urothelial and neuronal cells in normal mouse urinary bladder and are upregulated in inflammation. Am J Physiol Renal Physiol (2008) 0.98
Fatal emphysematous gastritis in a 2-year-old child with chronic renal failure. Pediatr Dev Pathol (2004) 0.98
PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer. Eur J Nucl Med Mol Imaging (2013) 0.98
The effect of amifostine or IMRT to preserve the parotid function after radiotherapy of the head and neck region measured by quantitative salivary gland scintigraphy. Radiother Oncol (2008) 0.97
Boron containing macromolecules and nanovehicles as delivery agents for neutron capture therapy. Anticancer Agents Med Chem (2006) 0.97
Self-assembled "dock and lock" system for linking payloads to targeting proteins. Bioconjug Chem (2006) 0.97
Causes and effects of hyperchloremic acidosis. Crit Care (2006) 0.96
Gallium-68-DOTA-albumin as a PET blood-pool marker: experimental evaluation in vivo. Nucl Med Biol (2005) 0.96
Ric-3 promotes alpha7 nicotinic receptor assembly and trafficking through the ER subcompartment of dendrites. J Neurosci (2010) 0.95
GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo. Cancer Res (2012) 0.95
Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using(68)Ga-DOTATOC PET and comparison with (18)F-FDG PET. Eur J Nucl Med Mol Imaging (2006) 0.95
Inhibition of anthrax protective antigen outside and inside the cell. Antimicrob Agents Chemother (2006) 0.94